
bioMérieux S.A.
BMXMF
Updated: 24/09/2026, 12:26:44
Operating on a global scale, bioMérieux S.A. designs and produces in vitro diagnostic solutions specifically for detecting infectious diseases across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The firm's offerings encompass diagnostic systems that analyze biological samples to identify infectious diseases, cardiovascular conditions, and various types of cancer. Furthermore, it provides essential microbiological testing for quality assurance within the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele includes clinical and hospital laboratories, medical professionals, blood banks, and industrial control facilities. Founded in 1963, initially under the name B-D Mérieux, bioMérieux S.A. is headquartered in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
No summaries found.
- Share price
- $83.27
- Market cap
- $9.82B
- Exchange
- OTC
- Currency
- USD
- CEO
- Pierre Boulud
- Employees
- 15,078
- IPO date
- 21/09/2017
- Beta
- 0.57
- Last dividend
- $0.00
- Day range
- $80.66 – $83.27
- 52-week range
- $77.00 – $135.01
- 1-day performance
- 0.00%
- 1-year performance
- 8.14%
- Current drawdown (1Y)
- -38.32%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- FR0013280286
- Created
- 07/12/2025, 03:03:03
- Last update
- 24/09/2026, 12:26:44
Track bioMérieux S.A. with an AI analyst
See which prediction-market events move BMXMF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.